Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Correlation Between Serum Tumor Marker Level and Stage,Therapeutic Response and Survival in Patients with Lung Cancer

CHEN Wu,SUN Yan-li,XI Yan(Dept.of Nuclear Medicine,Jilin Provincial Cancer Hospital,Changchun 130012,China)  
To explore the correlation between serum tumor marker levels of CEA,NSE and CYFRA21-1 with stage,therapeutic response and survival time of patients with lung cancer,84 lung cancer patients were examined before and after chemotherapy and followed up for 5 years.The overall rate of positive tumor makers was 67.9%(57/84),with those of SCLC and NSCLC being 65.4%(17/26) and 69.0%(40/58),respectively.Positive percentage of CEA,NSE and CYFRA21-1 were 11.5%(3/26),57.7%(15/26) and 23.1%(6/26) respectively in SCLC patients,and 37.9%(22/58),20.7%(12/58) and 44.8%(26/58) respectively in NSCLC patients.In limitedly developed(LD) stage of SCLC,the positive percentage of above three tumor markers was 0%,13.3%(2/15) and 0%,respectively,while in extensively developed(ED) stage,they were 100%(3/3),86.7%(13/15) and 100%(6/6),respectively.The positive tumor marker rates were 13.6%(3/22),16.7%(2/12) and 11.5%(3/26) respectively,while they were 86.4%(19/22),83.3%(10/12) and 88.5%(23/26),respectively in NSCLC patients with stage Ⅳ.After chemotherapy,93.3%(14/15) of SCLC patients with positive NSE became normal,72.7%(16/22) and 92.3%(22/24) of NSCLC patients had serum CEA and CYFRA21-1 lowered or became normal respectively.The overall survival time of SCLC and NSCLC patients with positive tumor markers were 18.0 and 16.2 months respectively which were shorter than the patients with normal serum tumor markers.The serum level of tumor markers was related to tumor stage and response to therapy.The prognosis was poor and the survival time was shorter in patients with higher serum tumor markers.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved